APA (7th ed.) Citation

MF, R., EG, D., & ARA, R. (2024). Clinical activity of pembrolizumab in refractory MDM2-amplified advanced intimal sarcomas. Therapeutic advances in medical oncology, 16, 17588359241250158. https://doi.org/10.1177/17588359241250158

Chicago Style (17th ed.) Citation

MF, Ribeiro, Demicco EG, and Razak ARA. "Clinical Activity of Pembrolizumab in Refractory MDM2-amplified Advanced Intimal Sarcomas." Therapeutic Advances in Medical Oncology 16 (2024): 17588359241250158. https://doi.org/10.1177/17588359241250158.

MLA (9th ed.) Citation

MF, Ribeiro, et al. "Clinical Activity of Pembrolizumab in Refractory MDM2-amplified Advanced Intimal Sarcomas." Therapeutic Advances in Medical Oncology, vol. 16, 2024, p. 17588359241250158, https://doi.org/10.1177/17588359241250158.